Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer

Clinical Cancer Research

Volumn 9, Issue 7, 2003, Pages 2576-2582

  Durkan, Garrett C ^a   Nutt, Joyce E ^a   Marsh, Colin ^b   Rajjayabun, Paul H ^a   Robinson, Mary C ^b   Neal, David E ^a   Lunec, John ^a   Mellon, J Kilian ^a,c  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

^c LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; METALLOPROTEINASE INHIBITOR;

ADULT; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DATA ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN URINE LEVEL; STATISTICAL SIGNIFICANCE; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROGNOSIS; RECURRENCE; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 0037817366     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. MacDougall, J. R., and Matrisian, L. M. Contributions of tumour and stromal matrix metalloproteinases to tumour progression, invasion and metastasis. Cancer Metastasis Rev., 14: 531-362, 1995.
2. Chambers, A. F., and Matrisian, L. M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. (Bethesda), 89: 1260-1270, 1997.
3. Gomez, D. E., Alonso, D. F., Yoshiji, H., and Thorgeirsson, U. P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol., 74: 111-122, 1997.
4. Liotta, L. A., Tryggvason, K., Garbisa, S., Hart, I., Foltz, C. M., and Shafie, S. Metastatic potential correlates with enzymatic digestion of basement membrane collagen. Nature (Lond.), 284: 67-68, 1980.
5. r 92,000 gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells. Cancer Res., 50: 3872-3877, 1990.
6. MacDougall, J. R., Bani, M. R., Lin, Y., Rak, J., and Kerbel, R. S. The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells. Cancer Res., 55: 4174-4181, 1995.
7. Davies, B., Waxman, J., Wasan, H., Abel, P., Williams, G., Krausz, T., Neal, D., Thomas, D., Hanby, A., and Balkwill, F. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res., 53: 5365-5369, 1993.
8. Bianco, F. J., Jr., Gervasi, D. C., Tiguert, R., Grignon, D. J., Pontes, J. E., Crissman, J. D., Fridman, R., and Wood, D. P., Jr. Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade. Clin. Cancer Res., 4: 3011-3016, 1998.
9. Moses, M. A., Wiederschain, D., Loughlin, K. R., Zurakowski, D., Lamb, C. C., and Freeman, M. R. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res., 58: 1395-1399, 1998.
10. Gerhards, S., Jung, K., Koenig, F., Danittchenko, D., Hauptmann, S., Schnorr, D., and Loening, S. A. Excretion of metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology, 57: 675-679, 2001.
11. Hayakawa, T., Yamashita, K., Tanzawa, K., Uchijima, E., and Iwata, K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett., 298: 29-32, 1992.
12. Wossner, J. F. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J., 5: 2145-2152, 1991.
13. Durkan, G. C., Nutt, J. E., Rajjayabun, P. H., Neal, D. E., Lunec, J., and Mellon, J. K. Prognostic significance of matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in voided urine samples from patients with transitional cell carcinoma of the bladder. Clin. Cancer Res., 7: 3450-3456, 2001.
14. Gohji, K., Fujimoto, N., Fujii, A., Komiyama, T., Okawa, J., and Nakajima, M. Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res., 56: 3196-3198, 1996.
15. Fitzpatrick, J. M., West, A. B., Butler, M. R., Lane, V., and O'Flynn, J. D. Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. J. Urol., 135: 920-922, 1986.
16. Hall, R. R., Parmar, M. K., Richards, A. B., and Smith, P. H. Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy. Br. Med. J., 308: 257-260, 1994.
17. Hara, I., Miyake, H., Hara, S., Arakawa, S., and Kamidono, S. Significance of matrix metalloproteinases and tissue inhibitor of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder. J. Urol., 165: 1769-1772, 2001.
18. Ozdemir, E., Kakehi, Y., Okuno, H., and Yoshida, O. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas. J. Urol., 161: 1359-1363, 1999.
19. Union Internationale Contre le Cancer. TNM classification of malignant tumours. In: P. Hermaneck, R. V. P. Hunter, L. H. Sobin, G. Wagner, and C. Wittekind (eds.), TNM Atlas: Illustrated Guide to TNM/pTNM Classification, Ed. 4. Heidleberg: Springer-Verlag; 1997.
20. Mostofi, F. K. International histologic classification of tumors. A report by the Executive Committee of the International Council of Societies of Pathology. Cancer (Phila.), 33: 1480-1484, 1974.
21. Grignon, D. J., Sakr, W., Toth, M., Ravery, V., Angulo, J., Shamsa, F., Pontes, J. E., Crissman, J. C., and Fridman, R. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res., 56: 1654-1659, 1996.
22. Zeng, Z. S., and Guillem, J. G. Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases. Br. J. Cancer, 72: 575-582, 1995.
23. Fong, K. M., Kida, Y., Zimmerman, P. V., and Smith, P. J. TIMP1 and adverse prognosis in non-small cell lung cancer. Clin. Cancer Res., 2: 1369-1372, 1996.
24. Mimori, K., Mori, M., Shiraishi, T., Fujie, T., Baba, K., Haraguchi, M., Abe, R., Ueo, H., and Akiyoshi, T. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br. J. Cancer, 76: 531-536, 1997.
25. Ree, A. H., Florenes, V. A., Berg, J. P., Maelandsmo, G. M., Nesland, J. M., and Fodstad, O. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin. Cancer Res., 3: 1623-1628, 1997.
26. Hayakawa, T. Tissue inhibitors of metalloproteinases and their cell growth-promoting activity. Cell Struct. Funct., 19: 109-114, 1994.